Investment ThemesDetailed Quotes
Anti-Pandemic Concept
Watchlist
- 3489.897
- -48.680-1.38%
Trading Nov 5 10:35 ET
3511.475High3488.803Low
3509.619Open3538.577Pre Close18.14MVolume9Rise36.19P/E (Static)1.42BTurnover2Flatline0.11%Turnover Ratio1.87TMarket Cap14Fall1.84TFloat Cap
Constituent Stocks: 24Top Rising: NNVC+5.99%
Sign in to post a comment
$Eli Lilly and Co (LLY.US)$ what happend everthing is up a least lly
2
$Veru Inc (VERU.US)$
Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek
Veru Inc. presented a meta-analysis of enobosarm's effects on body composition in older obese patients at ObesityWeek 2024. The analysis, based on four previous clinical trials, showed that enobosarm 3mg treatment led to better outcomes compared to placebo. By Day 147, enobosarm-treated subjects showed greater...
Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek
Veru Inc. presented a meta-analysis of enobosarm's effects on body composition in older obese patients at ObesityWeek 2024. The analysis, based on four previous clinical trials, showed that enobosarm 3mg treatment led to better outcomes compared to placebo. By Day 147, enobosarm-treated subjects showed greater...
$Vaccinex (VCNX.US)$
Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
$Pfizer (PFE.US)$
According to the Securities Times APP, on November 5, the official website of the National Medical Products Administration (NMPA) showed that Pfizer's talazoparib tosylate capsules (talazoparib) have been approved for marketing. Talazoparib was originally developed by BioMarin, acquired by Medivation from BioMarin in 2015, and Pfizer acquired Medivation for $14 billion in 2016, thus talazoparib belongs to Pfizer since then.
According to the Securities Times APP, on November 5, the official website of the National Medical Products Administration (NMPA) showed that Pfizer's talazoparib tosylate capsules (talazoparib) have been approved for marketing. Talazoparib was originally developed by BioMarin, acquired by Medivation from BioMarin in 2015, and Pfizer acquired Medivation for $14 billion in 2016, thus talazoparib belongs to Pfizer since then.
1
$Pfizer (PFE.US)$ seize every opportunity to sell covered calls. the chart is bearish. The company massively overpaid to acquire Seagan using all cash, as a result they are pay $0.4 per share on interest expense annually. I dislike management who overpays to do M&A and/or share repurchase.
2
2
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Pfizer (PFE.US)$
10M in volume with over 5B free float.. This will always be a shorts paradise.. Too many outstanding shares for such a cheap stock!🤢🤮
10M in volume with over 5B free float.. This will always be a shorts paradise.. Too many outstanding shares for such a cheap stock!🤢🤮
1
1
$Pfizer (PFE.US)$
wow... talk about a sh*show with this stock!
wow... talk about a sh*show with this stock!
No comment yet
KopiKat : Perhaps a premonition of the upcoming election result?
Rafaelli88 OP KopiKat : The only stock fall